Clinical Advisory Board
Richard L. Schilsky
Member of the Clinical Advisory Board since April 2021
Education: MD, FACP, FSCT, FASCO
Background: Professor emeritus at the University of Chicago having recently retired from his position as Executive Vice President and Chief Medical Officer (CMO) of ASCO. Dr. Schilsky is also a past President of ASCO, having served in the role during 2008-2009, and former Board member of Conquer Cancer, the ASCO Foundation. Before joining ASCO in 2013, Dr. Schilsky spent the majority of his career at the University of Chicago where he joined the faculty in 1984. He is a highly respected leader in the field of clinical oncology and specializes in new drug development and treatment of gastrointestinal cancers.
Peter Michael Vestlev
Chief Medical Officer at Scandion Oncology and Chair of the Clinical Advisory Board
Education: MD, CBA, MPP
Background: Chief Physician, Oncologist, Region Zealand and Capital Region Previously, Head of Radiotherapy unit, Herlev Hospital, Head of Cooperating Cancer Departments, Head of research unit Roskilde Hospital, consultant for the Danish Medicines Agency, Chief Oncologist Capital Region.
Member of the Clinical Advisory Board since 2021
Education: MD, DMSc.
Background: Professor emeritus at University of Copenhagen and recently retired from his position as co-founder, CEO and CSO of Scandion Oncology A/S. Dr Brünner is former BoD member and Chairman for Preclinical Research, EORTC. Dr Brünner had his basic medical training in medical oncology at hospitals in Greater Copenhagen supplemented with an education in cellular and molecular biology from the National Cancer Institute and Georgetown University, USA. Dr Brünner has published more than 400 peer-reviewed scientific papers on translational cancer research.